...
首页> 外文期刊>Hormone and Metabolic Research >Second-generation thyrotropin receptor antibodies assay and quantitative thyroid scintigraphy in autoimmune hyperthyroidism.
【24h】

Second-generation thyrotropin receptor antibodies assay and quantitative thyroid scintigraphy in autoimmune hyperthyroidism.

机译:自身免疫性甲亢中的第二代促甲状腺激素受体抗体测定和甲状腺闪烁显像。

获取原文
获取原文并翻译 | 示例
           

摘要

Graves' disease (GD) is characterized by circulating TSH receptor antibodies (TRAb), and so-called hyperthyroid autoimmune thyroiditis (H-AIT) generally shows negative TRAb results with first-generation assays. However, a positive titer was observed in up to 13% of patients with euthyroid or hypothyroid autoimmune thyroiditis (AIT) by second-generation TRAb assays, and a larger increase is expected in hyperfunctioning forms. A thyroid 99mTc-pertechnetate uptake (TcTUs) cutoff of 2% previously was shown to accurately discriminate between GD and H-AIT. Here we evaluated the relationship between second-generation TRAb assays and TcTUs in 139 patients with untreated autoimmune hyperthyroidism. An increase in TRAb levels was found in 114 of 139 patients (82%). All patients with TcTUs 2% and 66% of those with lower values had positive TRAb measurements. When the cutoff was increased to 5.9 U/l, positive TRAb occurred in 92.6% of those having higher TcTUs and in 1.4% of those with lower TcTUs. TRAb levelssignificantly increased in patients with TcTUs higher than 2% as compared with those having lower values, while no differences occurred in patients with TcTUs ranging from 0 to 1%, from 1.1 to 1.5%, or from 1.6 to 2%. A significant relationship between TRAb and TcTUs (as well as fT3, fT4, and thyroid volume) was found. TcTUs, fT4, fT3, and thyroid volume significantly increased in patients with positive TRAb (cutoff 1.5 U/l) compared with those testing negative. Our data indicate that a large proportion of patients with hyperthyroidism and hypoechoic thyroid, including those previously diagnosed as having H-AIT, actually have circulating TRAb. TRAb levels predicate the degree of iodine uptake (as measured by TcTUs) and thyroid hyperfunction. The role of baseline TRAb measurement by second-generation assays to predict patients' outcome needs to be further evaluated and compared with TcTUs in prospective studies.
机译:格雷夫斯病(GD)的特征在于循环中的TSH受体抗体(TRAb),所谓的甲状腺功能亢进的自身免疫性甲状腺炎(H-AIT)通常在第一代检测中显示TRAb阴性。但是,通过第二代TRAb分析,在多达13%的甲状腺功能正常或甲状腺功能低下的自身免疫性甲状腺炎(AIT)患者中观察到了阳性滴度,并且在功能亢进形式中预期会有更大的上升。甲状腺99mTc-高tech酸盐摄取(TcTUs)先前的2%临界值显示可准确地区分GD和H-AIT。在这里,我们评估了139例未经治疗的自身免疫性甲亢患者的第二代TRAb检测与TcTU之间的关系。 139例患者中有114例(82%)的TRAb水平升高。所有TcTU> 2%的患者和66%较低值的患者的TRAb测量均为阳性。当临界值增加到5.9 U / l时,TcTU较高者中有92.6%和TcTU较低者中有1.4%出现TRAb阳性。 TcTUs高于2%的患者与较低值的患者相比TRAb水平显着增加,而TcTUs的范围从0%至1%,1.1%至1.5%或1.6%至2%没有差异。发现TRAb和TcTUs之间(以及fT3,fT4和甲状腺体积)之间存在显着关系。 TRAb阳性(临界值1.5 U / l)的患者的TcTUs,fT4,fT3和甲状腺体积显着高于阴性的患者。我们的数据表明,甲状腺功能亢进和甲状腺功能低下的患者,包括先前被诊断患有H-AIT的患者中,实际上有循环的TRAb。 TRAb水平决定了碘的摄取程度(通过TcTUs测量)和甲状腺功能亢进。通过第二代测定进行基线TRAb测量以预测患者预后的作用需要进一步评估,并与前瞻性研究中的TcTU进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号